• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
April 12, 2019 07:58 AM EDTUpdated April 15, 04:36 AM
Bioregnum
R&D
Opinion

Go­ing vi­ral? J&J tries to spark a Twit­ter­storm for the lat­est da­ta on its HIV med

When you set out to make a block­buster, can a Twit­ter­storm help?

About 9 months af­ter the FDA OK’d J&J’s 4-in-1 HIV pill Sym­tuza …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN
TRENDING NOW

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

RFK Jr. ends an­nu­al Covid vac­cine rec­om­men­da­tions for kids, preg­nant women

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News